Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
Geron Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 20, 2026 at 2:00 p.m. Eastern. Holders of 640,900,330 common shares as of March 26, 2026 may vote.
Proposals include electing three Class III directors, adding 4,500,000 shares to the 2018 Equity Incentive Plan, an advisory vote on executive pay, and ratifying Ernst & Young LLP as auditor for 2026. The meeting will be held online at www.virtualshareholdermeeting.com/GERN2026, where investors can attend, submit questions, and vote using their 16-digit control number.
Spiegel Robert J. reported acquisition or exercise transactions in this Form 4 filing.
Geron Corp director Robert J. Spiegel received 5,243 shares of common stock as part of his board compensation. The shares were granted in lieu of cash for his quarterly board retainer and committee fees, using a reference price of $1.49 per share based on the March 31, 2026 closing price. Following this stock award, he directly holds 199,707 Geron common shares.
The Vanguard Group filed an Amendment No. 1 to a Schedule 13G/A stating it beneficially owns 0 shares of Geron Corp, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries/divisions to report separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Geron Corp director Constantine Chinoporos received a grant of stock options, not an open-market share purchase. The award covers 270,000 options to buy Geron common stock at an exercise price of $1.57 per share and expires on March 24, 2036.
The options will vest in three equal annual installments starting on March 25, 2027, subject to his continuous service with the company through each vesting date. Following this grant, he holds 270,000 stock options directly according to the filing.
Geron Corp director files initial ownership report with no trades
Geron Corp director Constantine Chinoporos has filed an initial ownership statement as a company insider. This Form 3 filing establishes his status as a director of Geron Corp but does not report any stock transactions or derivative positions.
Geron Corporation director Patricia S. Andrews received a grant of 270,000 stock options to buy Geron common stock. The options have an exercise price of $1.57 per share and expire on March 24, 2036. They vest in three equal annual installments starting on March 25, 2027, contingent on her continued service. Following this grant, she holds 270,000 stock options directly.
Geron Corp director Patricia S. Andrews has filed an initial insider ownership report with the SEC. This Form 3 filing establishes her status as a director of Geron Corp (ticker GERN) and provides a baseline disclosure of her holdings, with no transactions reported in this filing.
Geron Corporation reported that its Board of Directors elected Patricia S. Andrews and Constantine Chinoporos as Class III directors, effective immediately, with terms running until the 2026 Annual Meeting of Stockholders. Andrews was also appointed to the Board’s Audit Committee.
Both new directors will receive cash and equity compensation under Geron’s standard non-employee director program and will enter into the company’s standard indemnification agreements, which can cover expenses such as attorneys’ fees and settlements related to their service as directors.
Geron Corporation is reported as being beneficially owned in the amount of 33,008,659 shares by Soleus-related filers, representing 5.2% of common stock. The percentage is calculated using February 20, 2026 outstanding share count of 640,544,661.
The shares are held directly by Soleus Capital Master Fund, L.P. and reported by affiliated entities and Guy Levy in a joint filing; the filing includes a disclaimer that the affiliated entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) reporting purposes.